Study Immunology and Safety of 60-day Treatment of SQ Grass SLIT (Sublingual Immunotherapy)-Tablet in Adult Subjects With Grass Pollen-induced Allergic Rhinoconjunctivitis

Inclusion Criteria:

• clinical history consistent with grass pollen-induced allergic rhinoconjunctivitis.

• Use of symptomatic treatment of grass pollen-induced allergic rhinoconjunctivitis.

• Positive skin prick test response (wheal diameter ≥3 mm) to Phleum pratense.

• If asthma, daily use of Inhaled corticosteroid (ICS) should be ≤400 microgrambudesonide or equivalent

• Moderate or higher level of Phleum pratense specific IgE (Immunoglobulin E) (definedas ≥IgE Class 2; or ≥0.70 Kilo Units/liter (kU/L))

Exclusion Criteria:

• Reduced lung function (defined as FEV1 < 70% (FEV1=Forced Expiratory Volume in 1second) of predicted value after adequate pharmacologic treatment) measured at Visit 1and Visit 2

• Clinical history of uncontrolled asthma within 3 months prior to the screening visit